Watch More Highlights
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses important data that advanced practitioners need to know about bispecific antibodies in the pipeline such as mosunetuzumab, glofitamab, and epcoritamab and how they may fit into the treatment paradigm; new antibody-drug conjugates; and how to sequence the agents, manage their toxicities, and deliver supportive care.